L-ornithine L-aspartate
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07117630 | Sep 2025 → Jun 2027 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT00470314 | Jan 2005 → May 2007 | acute liver failure | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01440829 | Dec 2011 → Dec 2012 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Air Force Military Medical University, China | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00433368 | Oct 2003 → Sep 2004 | hepatic encephalopathy | Aga Khan University | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07037394 | Dec 2024 → Apr 2025 | hepatic encephalopathy | Qurratul Ain Jamil | Completed | No outcome recorded |
| Phase 4 | NCT05920213 | Oct 2023 → Apr 2024 | hepatic encephalopathy | Jinnah Postgraduate Medical Centre | Unknown | No outcome recorded |
| Phase 4 | NCT05737030 | Feb 2023 → Jul 2024 overdue | cirrhosis of liver | Medical University of Graz | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05042245 | Jul 2019 → Dec 2022 | NAFLD1 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02158182 | Jul 2014 → Jun 2016 | hepatic encephalopathy | Hospital General de Mexico | Completed | No outcome recorded |
| Phase 4 | NCT01722578 | Dec 2013 → Jan 2017 | cirrhosis of liver, hepatic encephalopathy | Dayanand Medical College and Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01041755 | Nov 2009 → Jun 2011 | hepatic encephalopathy | Centro Regional para el Estudio de las Enfermedades Digestivas | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05778461 | Mar 2023 → Oct 2024 | acute liver failure | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT00305591 | Mar 2006 → Oct 2007 | cirrhosis of liver, hepatic encephalopathy | Imperial College London | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 44 trials | ||||||
| Phase 4 | NCT05539027 Comparator | Sep 2022 → Oct 2024 | hepatic encephalopathy | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT01847651 Comparator | Aug 2013 → Jun 2015 | cirrhosis of liver, hepatic encephalopathy | Imperial College London | Completed | No outcome recorded |
| Phase 4 | NCT00896831 Comparator | Nov 2008 → Mar 2010 | hepatic encephalopathy | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT00740142 Comparator | Sep 2008 → Aug 2010 | hepatic encephalopathy | Mahidol University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06483737 Background | Jun 2025 → Jun 2027 expected | hepatic encephalopathy | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-ornithine L-aspartate | “There is no effective treatment available for hepatic encephalopathy at the moment; therefore we aimed to check the efficacy and safety of L-ornithine L-aspartate(LOLA).” NCT00433368 ↗17“Group D: LOLA (L-Ornithine L- Aspartate) concentrate for infusion (5g/10ml = 5g LOLA in 10ml clear solution) + lactulose.” NCT07037394 ↗ “Each 5g sachet contains 3g of L-ornithine L-aspartate” NCT01847651 ↗ |
| Known as | Hepa-Merz Granulat 3000 | “Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate)” NCT01847651 ↗ |
| Known as | Hepa-Merz granules 3g | “Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate)” NCT01847651 ↗ |
| Known as | LOLA | “The aim of this study is to evaluate the effectiveness of L-ornithine-L-aspartate (LOLA) on plasma ammonia in cirrhotic patients after Transjugular Intrahepatic Portosystemic...” NCT01440829 ↗8“There is no effective treatment available for hepatic encephalopathy at the moment; therefore we aimed to check the efficacy and safety of L-ornithine L-aspartate(LOLA).” NCT00433368 ↗ “Lactulose which is the standard of care treatment will be administered with the experimental drug L-ornithine L-aspartate (LOLA).” NCT05920213 ↗ “L-ornithine L-aspartate (LOLA), a salt of natural amino-acids ornithine and aspartate, is an importantammonia scavenging drug.” NCT05778461 ↗ “L-ornithine L-aspartate (LOLA) reduces ammonia levels by increasing hepatic ammonia disposal and its peripheral metabolism.” PMID 19505424 ↗ Jun 2009 “Group D: LOLA (L-Ornithine L- Aspartate) concentrate for infusion (5g/10ml = 5g LOLA in 10ml clear solution) + lactulose.” NCT07037394 ↗ “Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)” NCT05539027 ↗ “They will then be given L-ornithine L-aspartate (LOLA) to take orally for 4 weeks” NCT00305591 ↗ “L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day” NCT01847651 ↗ |
| Known as | Ornithine aspartate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05042245 ↗ |
| Known as | Ornithine aspartate granule | “Drug: Ornithine aspartate granule” NCT05042245 ↗ |
| Known as | Ornithine aspartate granules | “Ornithine aspartate granules in the experimental arm.” NCT05042245 ↗ |
| Action | Activate | “Hence LOLA can activate the periportal urea cycle.” NCT00470314 ↗ |
| Modality | Other / unclassified | “Amino acid combination” NCT05737030 ↗ |
| Route | Oral | “They will then be given L-ornithine L-aspartate (LOLA) to take orally for 4 weeks” NCT00305591 ↗ |